A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride

References

• Abrams P, Chapple C, Khoury S, et al Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779–87
   PubMed Web of Science ®Google Scholar
• Rosen RC, Fisher WA, Eardley I, et al The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607–17
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Nickel JC, Andriole GL, et al Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011;78:641–6
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793–803
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin J, van Erps P, et al Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488–94. discussion 95
   PubMed Web of Science ®Google Scholar
• Clark RV, Hermann DJ, Cunningham GR, et al Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179–84
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Marks LS, Fenter T, et al Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709–15
   PubMed Web of Science ®Google Scholar
• Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009;16:745–50
   PubMed Web of Science ®Google Scholar
• Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 1998;63:208–13
   PubMed Web of Science ®Google Scholar
• Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol 2011;52:632–6
   PubMedGoogle Scholar
• Demir O, Akgul K, Akar Z, et al Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29–34
   PubMed Web of Science ®Google Scholar
• Tsai CC, Liu CC, Huang SP, et al The impact of irritative lower urinary tract symptoms on erectile dysfunction in aging Taiwanese males. Aging Male 2010;13:179–83
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–26
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Goldstein I, Bushmakin AG, et al Validation of the erection hardness score. J Sex Med 2007;4:1626–34
   PubMed Web of Science ®Google Scholar
• Wu XJ, Zhi Y, Zheng J, et al Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients. Urology 2014;83:539–43
   PubMed Web of Science ®Google Scholar
• Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011;73:598–603
   PubMed Web of Science ®Google Scholar
• Mondaini N, Gontero P, Giubilei G, et al Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708–12
   PubMed Web of Science ®Google Scholar
• Silvestri A, Galetta P, Cerquetani E, et al Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003;24:1928–32
   PubMed Web of Science ®Google Scholar
• Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology 2009;112:174–7
   PubMed Web of Science ®Google Scholar
• Casabe A, Roehrborn CG, Da Pozzo LF, et al Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014;191:727–33
   PubMed Web of Science ®Google Scholar
• Burns PR, Rosen RC, Dunn M, et al Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med 2015;12:720–7
   PubMed Web of Science ®Google Scholar
• Glina S, Roehrborn CG, Esen A, et al Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med 2015;12:129–38
   PubMed Web of Science ®Google Scholar
• Park MG, Yeo JK, Cho DY, et al The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966–74
   PubMed Web of Science ®Google Scholar
• Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997;138:3925–32
   PubMed Web of Science ®Google Scholar
• Garban H, Marquez D, Cai L, et al Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod 1995;53:1365–72
   PubMed Web of Science ®Google Scholar
• Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495–501
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Gur S, Tracey AJ, et al The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011;8:3066–74
   PubMed Web of Science ®Google Scholar
• Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010;76:1446–50
   PubMed Web of Science ®Google Scholar
• Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol 2001;8:53–9
   PubMed Web of Science ®Google Scholar
• Traish AM, Hassani J, Guay AT, et al Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872–84
   PubMed Web of Science ®Google Scholar